CAR-PRISM Trial Reports Promising Results in High-Risk Smoldering Multiple Myeloma

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

​Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade si…

CAR-T Trial Raises Prospect of Preventing Myeloma in High-Risk Group

(MedPage Today) -- SAN DIEGO -- Ciltacabtagene autoleucel (cilta-cel, Carvykti) as primary therapy induced deep and durable responses in every patient in a small phase II trial of high-risk smoldering multiple myeloma, a precursor to the active...

Cilta-Cel Produces Early Responses in Smoldering Multiple Myeloma

All patients who received cilta-cel in the phase 2 CAR-PRISM trial achieved MRD negativity per next-generation sequencing.

Carvykti shows promise before multiple myeloma; two megarounds; AZ wins in COPD and kidney disease

Carvykti shows promise in patients before full-blown multiple myeloma: Researchers from Dana-Farber Cancer Institute shared that 20 patients with high-risk smoldering multiple myeloma all saw signs of their disease go away after receiving Carvykti, a ...

Dana-Farber Phase 2 Trial Shows Deep and Lasting Responses to CAR T-Cell Therapy for High-Risk Smoldering Multiple Myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade sid…

Dana-Farber Phase 2 Trial Demonstrates Durable and Profound Responses to

In a groundbreaking advancement for blood cancer therapies, Dana-Farber Cancer Institute has presented compelling results from the phase 2 CAR-PRISM clinical trial, heralding a new era in the treatment of high-risk smoldering multiple myeloma (SMM). This investigation uniquely explored the application of Chimeric Antigen Receptor (CAR) T-cell therapy at an earlier, precancerous disease stage, revealing […]